What are the side effects of Rucaparib?

In clinical studies of rucaparib (Rucaparib) in the treatment of ovarian cancer, the most common (≥10%) adverse reactions were nausea, asthenia/fatigue, anemia/low hemoglobin, increased AST/ALT, vomiting, diarrhea, decreased appetite, thrombocytopenia/low platelet count, dysgeusia, neutropenia/low neutrophil count, increased serum creatinine, dyspnea, dizziness, indigestion, and photosensitivity reactions.

In clinical studies using rucapanib for the treatment of prostate cancer, adverse reactions that occurred in ≥20% of include fatigue, nausea, constipation, vomiting, diarrhea, anemia, thrombocytopenia, decreased appetite, rash, and increased AST/ALT. In the prescribing information of rucapanib, warnings and precautions including myelodysplastic syndrome/acute myeloid leukemia, embryo-fetal toxicity, etc. may also appear. Women should not breastfeed during treatment with rucapanib and for at least 2 weeks after treatment; based on the results of genotoxicity and animal reproduction studies, men should not donate sperm during treatment and for 3 months after treatment.

The original drug Rucapani has not yet been marketed in the country, so it has not entered the medical insurance coverage standards. The European version of rucapani original drug, specifications300mg*60 tablets sold overseas may cost more than 20,000 yuan per box (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheap generic rucapani drugs available overseas, and their pharmaceutical ingredients are basically the same as those of the original rucapani drug. For example, in India, the price of BDR pharmaceutical specifications of 300mg*60 tablets per box may be more than 6,000 yuan (the price may fluctuate due to exchange rate effects).